Real-world efficacy and safety of later-line ICIs in a large multi-center dataset of Korean patients having PD-L1-positive R/M-NSCLC
Latest Information Update: 30 Jul 2021
At a glance
- Drugs Nivolumab (Primary) ; Pembrolizumab (Primary)
- Indications Adenocarcinoma; Non-small cell lung cancer
- Focus Adverse reactions; Therapeutic Use
- 01 Aug 2021 Results published in the Journal of Cancer Research and Clinical Oncology
- 30 Jul 2021 New trial record